LEXICON
No.105 March 12, 2012

Drug marketing license (authorization) holder; drug marketer
医薬品製造販売業者
First-class drug marketing license (authorization) holder; first-class drug marketer
第1種医薬品製造販売業者
Second-class drug marketing license (authorization) holder; second-class drug marketer
第2種医薬品製造販売業者

The Pharmaceutical Affairs Law (PAL;薬事法) which went into effect in April 2005 separated drug manufacturing (製造) from marketing (製造販売), allowing companies without their own manufacturing facilities (製造設備) to market drugs manufactured by other companies (manufacturing license holders;製造業者). Drug marketing license...

To read the full story

LEXICON

By Izuru Ando

While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…

By Philip Carrigan

As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…

Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…